Financial Performance - The net profit attributable to shareholders for 2022 was RMB 23,331,394.53, representing a profit margin of approximately 21.43% of the total profit distributed to shareholders[6]. - The company plans to distribute a cash dividend of RMB 1.25 per 10 shares, totaling RMB 5,000,000.00, based on a total share capital of 40 million shares as of December 31, 2022[6]. - As of December 31, 2022, the company's distributable profits amounted to RMB 100,659,989.86[6]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2022 was approximately ¥303.85 million, representing a year-over-year increase of 3.95% compared to ¥292.31 million in 2021[23]. - Net profit attributable to shareholders decreased by 63.89% to approximately ¥23.33 million from ¥64.62 million in 2021[23]. - The basic earnings per share fell by 71.16% to ¥0.62, while diluted earnings per share decreased by 71.36% to ¥0.61[24]. - The net cash flow from operating activities dropped by 107.51%, resulting in a negative cash flow of approximately ¥4.09 million[25]. - The company's total assets increased by 187.56% to approximately ¥1.09 billion, up from ¥378.61 million in 2021[23]. - The company reported a total revenue of 13,000.00 million RMB, with a net profit of 3,155.65 million RMB, reflecting a significant increase in performance compared to the previous year[81]. Research and Development - Research and development expenses grew by 29.91%, accounting for 11.25% of operating revenue, up from 9% in the previous year[24]. - The company applied for 50 patents, including 28 invention patents and 22 utility model patents, enhancing its competitive barrier[36]. - The company has developed a fully automated nucleic acid detection system that can process samples without manual intervention, achieving a "sample in, result out" workflow, significantly improving efficiency[45]. - The company has established a comprehensive core technology system for molecular diagnostic reagents, enhancing its competitive edge in the market[73]. - The total R&D investment for the year was approximately ¥34.19 million, representing a 29.91% increase from the previous year, with R&D expenses accounting for 11.25% of total revenue[78]. Market and Product Development - The company is actively involved in the development of new diagnostic technologies and products, aiming to expand its market presence[12]. - The company’s strategic focus includes enhancing its product offerings and exploring potential mergers and acquisitions to drive growth[12]. - The company has developed a range of molecular diagnostic reagent products, including the first SAT-based nucleic acid test kits for Chlamydia trachomatis and Neisseria gonorrhoeae in China, addressing unmet clinical needs[41]. - The company launched the world's first HBV RNA detection product for hepatitis B, which is now used in several provinces including Shandong and Fujian[64]. - The company aims to become a leading developer and supplier of molecular diagnostic products, focusing on unmet clinical needs in the RNA diagnostics field[138]. Corporate Governance - The company has not yet achieved profitability since its listing[4]. - The company does not have any special arrangements for corporate governance[8]. - The company has established a governance framework that includes a board of directors, supervisory board, and various specialized committees to ensure effective oversight and decision-making[142]. - There were no significant differences between the company's governance practices and the regulations set forth by the China Securities Regulatory Commission[142]. - The company has maintained a presence in academic institutions, with board members holding positions at universities, which may facilitate research collaborations and innovation[155]. Operational Risks and Challenges - The company faces challenges due to a shift in revenue structure, leading to a decrease in gross profit contribution[26]. - The company is exposed to competition from both domestic and international players, which may impact its market position if it cannot maintain technological leadership[96]. - The company must navigate regulatory challenges, as new products require extensive approval processes that can take 3-5 years[94]. - The company is at risk of new product development failures due to high costs, long cycles, and potential misalignment with market needs[93]. - The company faces risks related to significant revenue declines if conventional business growth cannot offset declines in pandemic-related business[92]. Environmental and Social Responsibility - The company invested 4.8 million yuan in environmental protection during the reporting period[191]. - The company is not listed as a key pollutant discharge unit and has no instances of exceeding emission standards[192]. - The company has established an environmental protection management system and has clear responsibilities for waste disposal and emissions[195]. - The company donated 81.23 million yuan to local Red Cross societies to support pandemic prevention efforts[197]. Future Outlook - The company anticipates continued growth in the in vitro diagnostic market, driven by an aging population and rising healthcare demands[134]. - The molecular diagnostics market is expected to lead the in vitro diagnostics industry, with applications in various medical fields[134]. - The molecular diagnostics market in China is expected to grow rapidly, driven by increasing clinical demand and technological advancements, with a focus on RNA diagnostics[135]. - The Chinese government is promoting a health-centered approach, emphasizing early screening and prevention in infectious disease management, which will benefit RNA diagnostics[137].

Financial Performance - The company's operating revenue for Q1 2023 was ¥38,766,500.34, representing a decrease of 58.44% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥6,392,335.66, reflecting a decline of 138.03% year-over-year[5]. - Basic and diluted earnings per share were both -¥0.16, down 128.57% from the same period last year[6]. - Total operating revenue for Q1 2023 was ¥38,766,500.34, a decrease of 58.5% compared to ¥93,280,166.18 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥6,392,335.66, compared to a profit of ¥16,806,634.77 in Q1 2022, representing a significant decline[20]. - The company experienced a comprehensive loss of ¥6,909,010.22 in Q1 2023, compared to a comprehensive income of ¥16,784,019.05 in Q1 2022[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,213,384.20, a decrease of 204.23% compared to the previous year[6]. - In Q1 2023, the net cash flow from operating activities was -$6,213,384.20, a significant decline from $5,961,279.66 in Q1 2022[24]. - Total cash inflow from operating activities was $67,228,828.74, down from $74,655,779.92 in the same quarter last year, representing a decrease of approximately 10.5%[24]. - Cash outflow from operating activities increased to $73,442,212.94 from $68,694,500.26, marking an increase of about 6.5% year-over-year[24]. - The total cash and cash equivalents at the end of Q1 2023 were $273,236,061.29, down from $875,430,465.48 at the end of Q1 2022, reflecting a decrease of approximately 68.9%[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,066,374,019.29, a decrease of 2.05% from the end of the previous year[6]. - Total liabilities decreased to ¥110,652,691.07 in Q1 2023 from ¥127,337,004.79 in Q1 2022, indicating a reduction of 13.1%[17]. - The company's total assets as of Q1 2023 were ¥1,066,374,019.29, a decrease from ¥1,088,721,710.38 in the previous year[17]. Research and Development - Research and development expenses totaled ¥8,518,167.13, an increase of 17.21% year-over-year, accounting for 21.97% of operating revenue, up 12.35 percentage points[6]. - Research and development expenses increased to ¥8,518,167.13 in Q1 2023, up from ¥7,267,729.68 in Q1 2022, reflecting a focus on innovation[20]. - The company is accelerating multiple ongoing projects to enhance future growth potential, which contributed to the increase in R&D expenses[9]. Shareholder Information - The top shareholder,居金良, holds 19.65% of the shares with a total of 7,858,357 shares[12]. - MING LI INVESTMENTS LIMITED is the second-largest shareholder with 15.44%, holding 6,176,624 shares[12]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[13]. Operational Insights - The decline in revenue was attributed to a significant drop in pandemic-related testing products, despite a recovery in routine testing reagent business[9]. - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[14]. - The company has not provided specific guidance for future performance or market expansion plans in this report[14].

证券代码：688193 证券简称：仁度生物 公告编号：2023-014 届时公司的董事长居金良先生、董事兼总经理于明辉女士、董事兼副总经理 曹若华女士、独立董事徐宗宇先生、董事会秘书兼财务总监蔡廷江先生将通过网 络在线交流形式与投资者就公司治理、发展战略、经营状况、现金分红方案、可 持续发展等投资者关注的问题进行沟通；如有特殊情况，上述参会人员可能进行 调整。 欢迎广大投资者积极参与。 特此公告。 上海仁度生物科技股份有限公司董事会 2023 年 4 月 26 日 为进一步加强与广大投资者的沟通交流，上海仁度生物科技股份有限公司 （以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说明会" 活动。现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录"上证路演中 心"网站（http://roadshow.sseinfo.com）或关注微信公众号"上证路演中心" 参与活动，活动时间为 2023 年 5 月 10 日（周三）15:00 至 17:00。 上海仁度生物科技股份有限公司 关于参加 2023 年上海辖区上市公司年报集体 业绩说明会的公告 本公司董事会及全体董事保证 ...

证券简称：仁度生物 证券代码：688193 上海仁度生物科技股份有限公司 投资者关系活动记录表 （2022 年 4 月） | --- | --- | --- | |------------------------|----------------------------------|-----------------------------------------------------| | | | | | | ☑ | 特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话会议 | | | □其他 | （请文字说明其他活动内容） | | | | 诺德基金、深圳泽正私募证券投资基金管理有限公司、 | | 参与单位名称 | 理有限公司 | 深圳市泰聚私募证券基金管理有限公司、中庚基金管 | | | | | | 会议时间 2022 | 年 4 月 | | | 参会方式 通讯方式 | | | | 上市公司接待人员姓名 | 董事长： 居金良 | | | | 董事兼总经理： 杨孝华 | | | | 董事兼副总 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥70,433,694.06, a decrease of 15.57% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,833,062.99, down 89.92% year-on-year, while the net profit after deducting non-recurring gains and losses was a loss of ¥4,661,307.85, a decrease of 127.80%[5] - The company reported a basic earnings per share of ¥0.08, down 86.89% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached ¥240,095,689.86, an increase of 7.3% compared to ¥223,558,205.60 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥23,754,699.23, a decrease of 53.7% compared to ¥51,221,003.23 in the same period of 2021[21] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 24,596,836, a decrease from CNY 51,183,075 in Q3 2021, representing a decline of approximately 52%[22] - Basic earnings per share for Q3 2022 were CNY 0.71, down from CNY 1.71 in Q3 2021, reflecting a decrease of about 58%[22] Expenses and Costs - Research and development expenses totaled ¥11,411,247.87, an increase of 55.49% year-on-year, accounting for 16.20% of operating revenue, up 7.40 percentage points[6] - Total operating costs for the first three quarters of 2022 were ¥220,908,652.51, up 31.9% from ¥167,482,998.67 in the previous year[20] - Research and development expenses for the first three quarters of 2022 amounted to ¥26,085,664.60, an increase of 44.3% from ¥18,077,334.81 in the previous year[20] - The company’s financial expenses showed a net income of -¥2,969,612.75, compared to -¥1,288,575.20 in the previous year, indicating a worsening financial position[20] Assets and Liabilities - Total assets reached ¥1,086,541,740.11, representing a year-on-year increase of 186.98%[6] - Total liabilities as of the end of Q3 2022 were ¥120,260,478.88, compared to ¥90,860,601.43 at the end of Q3 2021, reflecting a year-over-year increase of 32.4%[19] - The company’s total current assets were reported at ¥975,116,140.92, compared to ¥282,537,896.95 in the previous year, showing a growth of approximately 245%[17] - The company’s total current liabilities increased to ¥91,879,525.49, compared to ¥66,306,799.11 in the previous year, marking a rise of 38.7%[19] - Total equity attributable to shareholders reached ¥966,281,261.23, significantly up from ¥287,747,428.24 in the same period last year[19] Cash Flow - Cash flow from operating activities was negative at -¥15,431,886.63, a decrease of 169.25%[6] - Net cash flow from operating activities for the first three quarters of 2022 was negative CNY 15,431,886.63, compared to positive CNY 22,284,045.82 in the same period of 2021[23] - Cash inflow from investment activities in the first three quarters of 2022 was CNY 744,498,273.44, significantly higher than CNY 23,340,056.29 in the same period of 2021[23] - The net cash flow from investment activities for the first three quarters of 2022 was negative CNY 110,972,110.31, compared to negative CNY 14,398,788.51 in the same period of 2021[23] - Cash inflow from financing activities for the first three quarters of 2022 was CNY 675,692,000, compared to CNY 3,000,000 in the same period of 2021[23] - The net increase in cash and cash equivalents for the first three quarters of 2022 was CNY 526,725,061.46, compared to CNY 5,174,896.68 in the same period of 2021[23] - The ending balance of cash and cash equivalents as of the end of Q3 2022 was CNY 723,992,494.80, up from CNY 176,775,609.59 at the end of Q3 2021[23] - The company reported a significant increase in cash received from investment recoveries, totaling CNY 737,110,730.59 in the first three quarters of 2022, compared to CNY 22,000,000 in the same period of 2021[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,481[12] - The report indicates that there are no significant changes in the shareholder structure or related party transactions that could impact the company's operations[15] Other Information - The company has not disclosed any new product launches or technological advancements during this quarter[15] - There were no significant mergers or acquisitions reported in the third quarter of 2022[15] - The company has not provided specific future guidance or market expansion strategies in the current report[15] - The company has not executed any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[22]

Financial Performance - The company reported a total revenue of 688 million CNY for the first half of 2022, reflecting a year-on-year increase of 15%[1]. - The gross profit margin for the period was 45%, indicating a stable performance compared to the previous year[1]. - The company's operating revenue for the first half of 2022 was ¥169,661,995.80, representing a 21.07% increase compared to ¥140,134,514.79 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥21,921,636.24, a decrease of 33.64% from ¥33,035,932.10 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,112,955.88, down 46.66% from ¥32,085,110.10 year-on-year[21]. - The net cash flow from operating activities was -¥5,296,678.95, a decline of 140.50% compared to ¥13,077,820.92 in the same period last year[21]. - The net profit attributable to shareholders decreased by 33.64%, primarily due to a decline in sales revenue and gross margin of COVID-19 testing products[22]. - Operating cash flow decreased by 140.5% year-on-year, attributed to longer collection periods from some clients despite increased testing service revenue[22]. - The company achieved operating revenue of 169.66 million yuan, a year-on-year increase of 21.07%[71]. - The net profit attributable to shareholders decreased by 33.64% to CNY 21.92 million[85]. Market Expansion and Product Development - The company has set a revenue guidance of 1.5 billion CNY for the full year 2022, representing a growth target of 10%[1]. - New product launches included two innovative diagnostic kits, which are expected to contribute an additional 200 million CNY in revenue by the end of the year[1]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by Q4 2022[1]. - The company is focusing on expanding its product offerings in RNA molecular diagnostics, which is increasingly recognized for its clinical advantages over DNA diagnostics[41]. - The company has developed RNA detection products for various infections, including chlamydia, gonorrhea, and tuberculosis, leveraging the higher RNA copy numbers for more sensitive and accurate results[42]. - The company has successfully launched the AutoSAT, the first domestic high-throughput fully automated RNA nucleic acid detection analysis system, which streamlines the entire process from extraction to result analysis[47]. - The company has developed a new HBV RNA testing kit, addressing a market of approximately 70 million hepatitis B patients in China[73]. - The company is developing a fully automated nucleic acid detection system, which is expected to enhance testing capabilities across various sample types[56]. Research and Development - Research and development expenses increased by 25% to 100 million CNY, focusing on enhancing RNA detection technologies[1]. - R&D investment as a percentage of operating income increased by 0.99 percentage points to 8.65%[22]. - R&D expenses increased by 36.66% year-over-year, totaling approximately ¥14.67 million compared to ¥10.74 million in the same period last year[51]. - The company is focusing on product development, accelerating clinical research and registration for over ten projects, including hepatitis C, HIV, and HPV RNA[52]. - The company has developed the AutoSAT, the first fully automated, high-throughput RNA detection system in China, capable of meeting emergency testing needs[63]. Risk Management and Compliance - The report emphasizes the importance of risk management strategies in addressing potential operational risks[1]. - The company faced risks related to the loss of core technical personnel, which could impact ongoing projects and competitive advantage[78]. - There is a risk of intensified market competition, particularly from established multinational companies in the molecular diagnostics sector[80]. - The company noted that local outbreaks of COVID-19 could lead to fluctuations in sales and operational performance[82]. - The company emphasized the importance of maintaining effective quality control across its production processes to safeguard its reputation and operational integrity[83]. Shareholder Commitments and Corporate Governance - The controlling shareholder, Ju Jinliang, has committed to avoiding any business activities that may compete directly or indirectly with the company's main business during his tenure as the actual controller[113]. - The company will not engage in any related party transactions that could harm the interests of the company and its shareholders[115]. - The company commits to a profit distribution policy prioritizing cash dividends, with a minimum cash dividend ratio of 80% during mature stages without significant capital expenditures[134]. - The company will ensure that any commitments made regarding shareholding and reduction are adhered to, or it will publicly explain the reasons for non-compliance[133]. - The company will take necessary measures according to relevant laws and regulations if it fails to fulfill commitments, including stopping cash dividends and salary payments[163]. Financial Position and Assets - Total assets at the end of the reporting period were ¥1,087,586,153.33, reflecting a 187.26% increase from ¥378,608,029.67 at the end of the previous year[21]. - Cash and cash equivalents reached ¥846,196,037.31, an increase of 327.50% compared to ¥197,942,433.34 in the previous period[92]. - Accounts receivable increased to ¥98,828,668.19, up 78.65% from ¥55,319,058.41, attributed to longer customer payment terms[92]. - Inventory rose to ¥26,478,402.14, a 36.59% increase from ¥19,385,461.30, mainly due to increased raw material and product reserves[92]. - Total liabilities increased to ¥51,719,367.98, a rise of 77.84% from ¥29,081,567.08, mainly due to increased payable expenses[92].

Financial Performance - The company's revenue for Q1 2022 was ¥93,280,166.18, representing a year-over-year increase of 7.43%[3] - The net profit attributable to shareholders decreased by 13.54% to ¥16,806,634.77[3] - The basic earnings per share for the period was ¥0.56, down 13.54% from the previous year[3] - The weighted average return on equity decreased by 2.95 percentage points to 5.66%[3] - Net profit for Q1 2022 was ¥16,806,634.77, down from ¥19,437,639.40 in Q1 2021, a decrease of about 13.4%[18] - The total comprehensive income for Q1 2022 was ¥16,784,019.05, compared to ¥19,480,470.18 in Q1 2021, a decrease of about 13.9%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 192.07% to ¥5,961,279.66[3] - The company's cash and cash equivalents as of March 31, 2022, amounted to RMB 874,755,465.48, significantly up from RMB 197,942,433.34 at the end of 2021, representing a growth of 341.5%[13] - Cash flow from operating activities generated a net amount of ¥5,961,279.66 in Q1 2022, up from ¥2,041,065.05 in Q1 2021, indicating a significant improvement[21] - Cash and cash equivalents at the end of Q1 2022 totaled ¥875,430,465.48, compared to ¥167,029,781.05 at the end of Q1 2021, reflecting a substantial increase[22] - Investment activities resulted in a net cash outflow of ¥3,466,731.24 in Q1 2022, an improvement from a net outflow of ¥5,099,308.39 in Q1 2021[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,083,745,413.96, an increase of 186.24% compared to the end of the previous year[4] - The total liabilities as of March 31, 2022, were RMB 124,399,111.98, up from RMB 90,860,601.43, indicating a growth of 37%[15] - Total current assets reached RMB 982,345,585.28, compared to RMB 282,537,896.95 at the end of 2021, marking an increase of 248.5%[13] - The total equity attributable to shareholders increased by 233.40% to ¥959,346,301.98[4] - The total equity attributable to shareholders increased to RMB 959,346,301.98 from RMB 287,747,428.24, a rise of 233.5%[15] Research and Development - Research and development expenses amounted to ¥7,267,729.68, accounting for 7.79% of revenue, an increase of 0.14 percentage points[4] - Research and development expenses rose to ¥7,267,729.68 in Q1 2022, compared to ¥6,643,350.37 in Q1 2021, an increase of approximately 9.4%[17] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16] Strategic Outlook - The company reported non-recurring gains of ¥705,846.34 after tax[7] - The company reported a net profit margin improvement, with net profit for Q1 2022 expected to reflect positive growth trends[16] - The company has plans for strategic partnerships and potential acquisitions to bolster its market position and drive future growth[16] - The management provided optimistic guidance for the upcoming quarters, anticipating continued revenue growth and improved operational efficiency[16] Operating Costs - Total operating costs increased to ¥73,195,654.95 in Q1 2022 from ¥62,782,489.99 in Q1 2021, representing an increase of approximately 17.5%[17] - Total operating revenue for Q1 2022 was RMB 93,280,166.18, an increase of 7.8% compared to RMB 86,825,799.85 in Q1 2021[16] - Total revenue from sales of goods and services received cash of ¥74,344,188.17 in Q1 2022, down from ¥85,652,644.15 in Q1 2021, a decline of about 13.5%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,049[9] - The company recorded investment income of ¥735,301.12 in Q1 2022, significantly higher than ¥114,622.64 in Q1 2021, marking an increase of approximately 540.5%[17]